Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H6F3N |
| Molecular Weight | 161.1244 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(C=C1)C(F)(F)F
InChI
InChIKey=ODGIMMLDVSWADK-UHFFFAOYSA-N
InChI=1S/C7H6F3N/c8-7(9,10)5-1-3-6(11)4-2-5/h1-4H,11H2
| Molecular Formula | C7H6F3N |
| Molecular Weight | 161.1244 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis of ribosomal proteins in developing Dictyostelium discoideum cells is controlled by the methylation of proteins S24 and S31. | 2002 |
|
| A novel synthesis of (E)-3-methylthio-3-substituted arylamino-2-cyanoacrylates under microwave irradiation. | 2005 Oct 31 |
|
| Spectrophotometric stability-indicating methods for the determination of leflunomide in the presence of its degradates. | 2006 Nov-Dec |
|
| Synthesis and cytotoxicity studies of novel [1,2,4]triazolo[1,5-a]pyrimidine-7-amines. | 2008 Jul |
|
| N-(2-Ferrocenylethyl-idene)-4-(trifluoro-meth-yl)aniline. | 2009 Mar 28 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:06:02 GMT 2023
by
admin
on
Sat Dec 16 01:06:02 GMT 2023
|
| Record UNII |
RQJ623MB8G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10337
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY | |||
|
RQJ623MB8G
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY | |||
|
9964
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY | |||
|
DTXSID5060013
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY | |||
|
1357045
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY | |||
|
207-236-5
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY | |||
|
40750
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY | |||
|
455-14-1
Created by
admin on Sat Dec 16 01:06:03 GMT 2023 , Edited by admin on Sat Dec 16 01:06:03 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
4-TFMA was not detected in the single dose metabolism study, but was detected in very small amount after repeated dosing in clinical trials 4-TFMA plasma concentrations were measurable at relatively low concentrations after repeated teriflunomide doses of 7 mg (≤1.7 ng/mL) and 14 mg (≤5.31 ng/mL) for 468 weeks.
MINOR
|
||
|
PARENT -> METABOLITE |
Leflunomide is metabolized to one primary (M1) and many minor metabolites. Of these minor metabolites, only 4-trifluoromethylaniline (TFMA) is quantifiable
MINOR
PLASMA
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
UNSPECIFIED
USP
|